Latest news with #EDDC
Yahoo
3 days ago
- Business
- Yahoo
Radius CoWork, EDDC create new position to support local small businesses
Radius CoWork and the Erie Downtown Development Corporation (EDDC) are teaming up to support small businesses. Both organizations have created a new business support coordinator role that will provide expert resource advice for Erie's entrepreneurial community. Erie Insurance moves up on Fortune 500's list of America's largest corporations Financial consultant and business advisor Jenessa Norton has been hired to further EDDC's initiative to revitalize the downtown area. Downtown leaders said there's huge demand for business services in Erie, and they believe this effort will grow. Erie Co. owes over $500,000 after ECGRA audit comes back clean 'This role is going to enable us to accelerate both the start of new entrepreneurial ventures small businesses in our community to accelerate the growth of those businesses so that they get bigger faster that they provide new jobs and more ecnomic opportunity in our community so ofcourse were on a really great trajectory for over a decade but erie needs to pick up the pace,' said Sean Fedorko, founder and executive director of Radius CoWork. The position is funded through the Shaping Tomorrow grant from the Erie Community Foundation.s Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Cision Canada
3 days ago
- Business
- Cision Canada
Experimental Drug Development Centre Announces the Presentation of Updated Data from the Phase 1 Study of Antibody-Drug Conjugate EBC-129 at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO)
EBC-129 is an antibody-drug conjugate (ADC) that selectively targets a novel, tumour-specific N-glycosylated epitope found on both CEACAM5 and CEACAM6. The expansion cohort for pancreatic ductal adenocarcinoma (PDAC) in the ongoing Phase 1 trial has completed enrolment. Notably, 82% of patients had tumours expressing the antigen at levels considered treatable with EBC-129. EBC-129 demonstrated positive overall response rates and prolonged progression-free survival in PDAC patients that have been heavily pre-treated, including those that have received prior treatment with standard of care (SoC) typically containing taxanes. The US FDA also recently granted Fast Track Designation for EBC-129 in the treatment of PDAC patients. SINGAPORE, June 3, 2025 /CNW/ -- The Experimental Drug Development Centre (EDDC), Singapore's national platform for drug discovery and development, has announced the presentation of updated clinical data for the ongoing Phase 1 trial for EBC-129 at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. EBC-129 is a first-in-class antibody drug conjugate (ADC) targeting a novel, tumour-specific N256-glycosylated epitope on CEACAM5 and CEACAM6. The updated findings showed promising efficacy data from 21 heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patients across the dose escalation and the dose expansion portions of the Phase 1 study. Patients received EBC-129 at doses between 1.8 and 2.2 mg/kg, given once every 3 weeks. 17 out of 21 patients (81%) of the patients had received prior treatment with taxanes. 82% of patients had tumours which expressed the EBC-129 antigen at ≥1% at 3+ intensity and were therefore considered treatable. The overall response rates (ORRs) were 25% and 20%, with disease control rates (DCRs) of 87.5% and 63.6% and progression-free survival (PFS) of 19 and 12 weeks for 1.8 mg/kg and 2.2 mg/kg, respectively. "Pancreatic adenocarcinoma remains one of the most challenging cancers to treat, particularly in the metastatic setting where resistance to standard therapies is common. The clinical signals observed with EBC-129 in refractory pancreatic adenocarcinoma, including tolerability, prolonged disease control and a confirmed response in a heavily pre-treated patient, are encouraging and clinically meaningful. Continued prioritisation of biology-guided trials targeting EBC-129 will be key to sustaining momentum in this important therapeutic effort," said Assistant Professor Robert W. Lentz, MD, Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz School of Medicine. This presentation follows the recent Fast Track Designation granted by the U.S. FDA for EBC-129 in the treatment of PDAC patients. This designation supports EDDC's efforts to accelerate the advancement of the programme through increased regulatory engagement and the potential for expedited review pathways. Other Results to Date The dose escalation study of the Phase 1 trial was open to all patients, while the ongoing dose expansion study comprises of three cohorts in PDAC, gastroesophageal adenocarcinoma (GEA) and tumour-agnostic patients with other immunohistochemistry (IHC)-positive solid tumours. Recruitment for the GEA and IHC-positive cohorts is still ongoing. EBC-129 showed a manageable safety profile in the 58 patients treated so far, with uncomplicated neutropenia and infusion-related reactions as the main treatment-related adverse events (TRAEs) observed. The EBC-129 antigen was also found to be highly expressed, with 52% to 100% of tumour tissues assessed during the trial showing moderate to high expression levels of ≥20% at 2+ and/or 3+. This included samples from gastroesophageal, appendiceal, colorectal and lung cancer patients, making EBC-129 a potentially viable treatment option for these cancers. "We have seen encouraging signs of efficacy of EBC-129 as a single-agent therapy, even in heavily pre-treated patients with metastatic pancreatic cancer. This, combined with the observed safety profile, underscores the promise of EBC-129 as a possible treatment option for PDAC patients. As a first-in-class ADC that targets both CEACAM5 and CEACAM6, EBC-129 has also shown potential against a range of other solid tumours, and we look forward to expanding clinical evaluations with the ongoing dose expansion cohorts and accelerating the development of EBC-129 to address critical unmet needs in cancer," said Professor Damian O'Connell, CEO of EDDC. About EBC-129 EBC-129 is an ADC that targets a tumour-specific N256-glycosylation site conserved on CEACAM5 and CEACAM6. CEACAM5 and CEACAM6 are known to have functional importance in tumour formation, migration and metastasis. In the ongoing trial, the tumour-specific marker is found to be widely expressed in multiple solid tumour types, including gastric, oesophageal, pancreatic, lung, colorectal, and appendiceal cancers, based on an analytically validated immunohistochemistry (IHC) assay. The payload used in EBC-129 is monomethyl auristatin E (MMAE), which has been extensively tested and approved for clinical use in other marketed ADCs, and has demonstrated synergy with PD-1 inhibitors. The ongoing Phase 1 trial of EBC-129 is assessing the safety and tolerability of EBC-129 as a single agent and in combination with pembrolizumab in patients with advanced solid tumours. Enrolment for the PDAC cohort in the Phase 1 dose expansion study is now complete, while recruitment continues for the gastroesophageal adenocarcinoma (GEA) and IHC-positive cohorts. About the Experimental Drug Development Centre The Experimental Drug Development Centre (EDDC) is Singapore's national platform for drug discovery and development, formed from the integration of the Experimental Therapeutics Centre (ETC), Drug Discovery and Development (D3), and Experimental Biotherapeutics Centre (EBC) in 2019. EDDC aims to develop therapeutics and diagnostics that save and improve the lives of patients in Singapore, Asia and around the world. Hosted by the Agency for Science, Technology and Research (A*STAR), EDDC works collaboratively with public sector and industry partners to translate the great science arising from Singapore's biomedical and clinical sciences R&D into innovative healthcare solutions. For more information about EDDC, please visit
Fox News
30-04-2025
- Business
- Fox News
REP. MIKE KELLY, SEN. TIM SCOTT AND SECRETARY SCOTT TURNER: Save the Opportunity Zones before it's too late
In 2017, Congress passed one of the most consequential pieces of legislation in the last quarter-century. When President Donald Trump signed the Tax Cuts & Jobs Act (TCJA), the law spurred economic growth the United States hadn't seen in a generation. Wages increased, and unemployment decreased. Americans were able to cash their paychecks and go home to their families with more money in their pockets. Now, eight years later, major TCJA provisions are up for renewal. Among them: Opportunity Zones, a successful, bipartisan piece of legislation that is transforming underserved communities in real time. Opportunity Zones have made an incredible impact across our nation. The Opportunity Zone (OZ) initiative allows investors from all over the United States to invest their capital gains earnings in economically distressed communities where new investments can be eligible for preferential capital gains tax treatment. Instead of sitting idle in a brokerage or bank account, this money is put to work in communities that have not seen significant private investment for some time. This pro-growth tax policy offers crucial incentives that do not cost American taxpayers a single cent. In 2017, this kind of policy may have seemed unbelievable to some within the Beltway. Despite the skepticism, OZs are actively transforming communities and creating economic opportunities for families in the poorest zip codes. Erie, Pennsylvania may best exemplify the economic benefits and the tangible changes Opportunity Zones can create in a relatively short period of time. In 2018, the city's downtown ZIP code, 16501, was named the poorest in Pennsylvania and among the poorest nationwide. However, through the potential of OZs, the stigma of Pennsylvania's poorest ZIP code served as a springboard for investment in the area. Shortly after TCJA was signed into law, a group of local residents recognized how Opportunity Zones could revitalize the city. Major employers, local universities and other organizations partnered to provide initial financial backing to form the Erie Downtown Development Corporation (EDDC). To date, EDDC has leveraged more than $115 million in private investment into downtown Erie, which has built 108 new fully occupied residences, revitalized and created more than 100,000 square feet of new commercial space, and established space for 25 new businesses. Overall, $400 million of long-term capital investment is at work, breathing new life into Downtown Erie. These investments have a proven track record of revitalizing small businesses and residential areas while fostering innovation in technology and manufacturing — an industry where South Carolina excels. Projects like the South Carolina Technology & Aviation Center (SCTAC) have generated over $6.1 billion in investments and created more than 18,000 new jobs in the local community. This further underscores the significance of Opportunity Zones, which have been and will continue to be impactful. Additionally, Opportunity Zones have played a significant role in assisting the revitalization of previously overlooked communities, transforming them into economic powerhouses. In Oconee County, South Carolina, investors transformed a textile mill built in 1875 along Lake Hartwell into 197 new residential apartments. The project also incorporated retail and recreational amenities, including the restoration of the historic dam and the creation of public green spaces and trails. Nationally, Opportunity Zones have generated $89 billion in private investment across more than 5,600 designated communities, and this investment spurred the creation of over 500,000 jobs in the first two years alone. According to a report released in March by the Economic Innovation Group (EIG), a bipartisan public policy organization based in Washington, D.C. The legislation also has a far-reaching impact — approximately one in 10 Americans live in an Opportunity Zone. That number could soon grow. The EIG report also indicates that OZs "caused an increase of 313,000 new residential addresses (not counting units currently under construction) in designated communities from Q3 2019 to Q3 2024 – roughly doubling the total amount of new housing added to these communities over that period." Moreover, the Council of Economic Advisors found that the Opportunity Zone designation alone caused a 3.4% increase in home values in these areas, which translated to an estimated tens of billions of dollars in new wealth for the Opportunity Zone residents who own their homes. In 2018, the city's downtown ZIP code, 16501, was named the poorest in Pennsylvania and among the poorest nationwide. However, through the potential of OZs, the stigma of Pennsylvania's poorest ZIP code served as a springboard for investment in the area. By empowering the private sector and cutting red tape, Opportunity Zones enable projects to move more efficiently and at a lower cost while simultaneously addressing one of the most pressing needs in low-income communities – quality affordable housing. From the very start of the 2017 tax law, we knew the Opportunity Zones initiative would be a gamechanger. It was made for shovel-ready projects in neighborhoods that needed the help the most. As we look ahead to 2025, the future is bright in places like Erie and Oconee County. The EDDC is preparing to break ground on another $22 million project, which includes 37,000 square-feet for commercial office and retail space. However, if Congress fails to extend TCJA and Opportunity Zones provisions expire, we could see projects years in the making completely upended overnight, along with the largest tax hike in modern history. It's critical that Congress extend, expand and make the 2017 tax cuts permanent so working families, small businesses, and communities nationwide can continue to receive the benefits of this legislation – and tax cuts at large – for years to come. Republican Tim Scott represents South Carolina in the United States Senate. He is author of the book, "America, a Redemption Story: Choosing Hope, Creating Unity." Secretary Scott Turner leads the U.S. Department of Housing and Urban Development. He previously served as executive director of the White House Opportunity and Revitalization Council, where he championed Opportunity Zones during the first administration of President Donald J. Trump.
Korea Herald
08-04-2025
- Business
- Korea Herald
Engine Biosciences and Experimental Drug Development Centre Partner to Advance Novel Therapies to Combat Cancer
SINGAPORE, April 8, 2025 /PRNewswire/ -- Engine Biosciences (Engine), a Singapore- and Silicon Valley-based biotechnology company pioneering precision medicine for cancer, announced a new partnership with the Experimental Drug Development Centre (EDDC), Singapore's national platform for drug discovery and development hosted by the Agency for Science, Technology and Research (A*STAR). This first-of-its-kind collaboration unites Engine's NetMAPPR platform and proprietary oncology intellectual property with EDDC's drug discovery and development expertise to create first-in-class precision cancer treatments. The first project under this partnership focuses on ENB-871, a novel pairing of a drug target and patient selection biomarkers discovered through Engine's NetMAPPR platform. This platform combines AI, computation, biology, and chemistry to identify, validate, and prioritise drug targets with strong clinical and commercial potential, driving the development of new therapies that exploit specific vulnerabilities in tumours. This program shows significant promise for treating tumours with particular genetic mutations that predict sensitivity to the ENB-871 targeted therapy, including breast, liver, kidney and prostate cancers – diseases afflicting large and growing patient populations in Singapore and worldwide. In total, the potential addressable population exceeds 500,000 patients per year. The teams will collaborate to develop small molecule degraders targeting ENB-871, including demonstration of in vivo efficacy. By bringing together Engine's proprietary technology and deep translational insights with EDDC's strengths in designing and developing therapies, this partnership aims to create targeted cancer treatments tailored to patients' specific profiles, improving treatment effectiveness and outcomes. Engine and EDDC may also identify additional drug targets and research programs for collaboration during the partnership. "We're excited by the synergies created by bringing together our two platforms, leveraging first-in-class Singapore research and innovation to advance transformative cancer therapies. This marks another key step in Engine's mission to develop more effective, targeted and safer drugs for cancer patients." said Jeffrey Lu, CEO and Co-Founder of Engine Biosciences. "The future of drug development lies in precision-driven innovation. Our partnership with Engine enables us to develop therapies tailored to specific patient populations through Engine's biomarker-driven patient selection approaches. We are particularly excited to launch our first collaborative project around monovalent small molecule degraders, building on EDDC's expanding capabilities in this field. Beyond this, we look forward to strengthening our partnership by advancing more precision therapies that have the potential to transform the lives of cancer patients in need," shared Damian O'Connell, CEO of EDDC. About Engine Biosciences Engine Biosciences (Engine) is a venture-backed Singapore and Silicon Valley based company discovering and developing impactful precision medicines by deciphering complex biology with integrated computation and experimentation, with particular depth in oncology gained over several years of substantial investment and focus. Having pinpointed many promising drug targets and predictive biomarkers for patients most likely to benefit, Engine is advancing its pipeline of oncology therapeutics towards the clinic internally and with collaborators, and in other disease areas through partnerships. Engine's team is motivated by opportunities to address significant unmet needs with more selective and effective precision medicines. For more information, please visit and follow Engine on LinkedIn. About EDDC The Experimental Drug Development Centre (EDDC) is Singapore's national platform for drug discovery and development, formed from the integration of the Experimental Therapeutics Centre (ETC), Drug, Discovery and Development (D3), and Experimental Biotherapeutics Centre (EBC) in 2019. EDDC aims to develop therapeutics and diagnostics that save and improve the lives of patients in Singapore, Asia and around the world. Hosted by the Agency for Science, Technology and Research (A*STAR), EDDC works collaboratively with public sector and industry partners to translate the great science arising from Singapore's biomedical and clinical sciences R&D into innovative healthcare solutions. For more information about EDDC, please visit
Yahoo
08-04-2025
- Business
- Yahoo
Engine Biosciences and Experimental Drug Development Centre Partner to Advance Novel Therapies to Combat Cancer
This marks the first-ever collaboration between Engine Biosciences and Experimental Drug Development Centre (EDDC), Singapore's national platform for drug discovery and development. The partnership will advance the development of first-in-class precision therapeutics for multiple cancer types that are highly prevalent in Singapore and globally, including breast, liver, kidney and prostate cancers. SINGAPORE, April 8, 2025 /PRNewswire/ -- Engine Biosciences (Engine), a Singapore- and Silicon Valley-based biotechnology company pioneering precision medicine for cancer, announced a new partnership with the Experimental Drug Development Centre (EDDC), Singapore's national platform for drug discovery and development hosted by the Agency for Science, Technology and Research (A*STAR). This first-of-its-kind collaboration unites Engine's NetMAPPR platform and proprietary oncology intellectual property with EDDC's drug discovery and development expertise to create first-in-class precision cancer treatments. The first project under this partnership focuses on ENB-871, a novel pairing of a drug target and patient selection biomarkers discovered through Engine's NetMAPPR platform. This platform combines AI, computation, biology, and chemistry to identify, validate, and prioritise drug targets with strong clinical and commercial potential, driving the development of new therapies that exploit specific vulnerabilities in tumours. This program shows significant promise for treating tumours with particular genetic mutations that predict sensitivity to the ENB-871 targeted therapy, including breast, liver, kidney and prostate cancers – diseases afflicting large and growing patient populations in Singapore and worldwide. In total, the potential addressable population exceeds 500,000 patients per year. The teams will collaborate to develop small molecule degraders targeting ENB-871, including demonstration of in vivo efficacy. By bringing together Engine's proprietary technology and deep translational insights with EDDC's strengths in designing and developing therapies, this partnership aims to create targeted cancer treatments tailored to patients' specific profiles, improving treatment effectiveness and outcomes. Engine and EDDC may also identify additional drug targets and research programs for collaboration during the partnership. "We're excited by the synergies created by bringing together our two platforms, leveraging first-in-class Singapore research and innovation to advance transformative cancer therapies. This marks another key step in Engine's mission to develop more effective, targeted and safer drugs for cancer patients." said Jeffrey Lu, CEO and Co-Founder of Engine Biosciences. "The future of drug development lies in precision-driven innovation. Our partnership with Engine enables us to develop therapies tailored to specific patient populations through Engine's biomarker-driven patient selection approaches. We are particularly excited to launch our first collaborative project around monovalent small molecule degraders, building on EDDC's expanding capabilities in this field. Beyond this, we look forward to strengthening our partnership by advancing more precision therapies that have the potential to transform the lives of cancer patients in need," shared Damian O'Connell, CEO of EDDC. About Engine BiosciencesEngine Biosciences (Engine) is a venture-backed Singapore and Silicon Valley based company discovering and developing impactful precision medicines by deciphering complex biology with integrated computation and experimentation, with particular depth in oncology gained over several years of substantial investment and focus. Having pinpointed many promising drug targets and predictive biomarkers for patients most likely to benefit, Engine is advancing its pipeline of oncology therapeutics towards the clinic internally and with collaborators, and in other disease areas through partnerships. Engine's team is motivated by opportunities to address significant unmet needs with more selective and effective precision medicines. For more information, please visit and follow Engine on LinkedIn. About EDDCThe Experimental Drug Development Centre (EDDC) is Singapore's national platform for drug discovery and development, formed from the integration of the Experimental Therapeutics Centre (ETC), Drug, Discovery and Development (D3), and Experimental Biotherapeutics Centre (EBC) in 2019. EDDC aims to develop therapeutics and diagnostics that save and improve the lives of patients in Singapore, Asia and around the world. Hosted by the Agency for Science, Technology and Research (A*STAR), EDDC works collaboratively with public sector and industry partners to translate the great science arising from Singapore's biomedical and clinical sciences R&D into innovative healthcare solutions. For more information about EDDC, please visit View original content to download multimedia: SOURCE Engine Biosciences Sign in to access your portfolio
